Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/1995
06/01/1995CA2224051A1 Intermediates for producing substituted indoles as phosphodiesterase type iv inhibitors
06/01/1995CA2224049A1 Intermediates for producing substituted indoles as phosphodiesterase type iv inhibitors
06/01/1995CA2177375A1 3-aryl-2-isoxazolines as antiinflammatory agents
06/01/1995CA2177289A1 Ssi tyrphostins and pharmaceutical compositions
06/01/1995CA2177084A1 Therapeutic guanidines
06/01/1995CA2177081A1 Therapeutic substituted guanidines
06/01/1995CA2176251A1 Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
06/01/1995CA2176140A1 Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
06/01/1995CA2175828A1 Purine compositions and methods for administration
06/01/1995CA2174838A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
06/01/1995CA2154475A1 4,5-diphenylimidazole derivatives, their preparation and their use as acyl coenzyme a: cholesterol-0-acyl-transferase (acat) inhibitor
05/1995
05/31/1995EP0655462A1 Linear adhesion inhibitors
05/31/1995EP0655460A1 Pharmacotherapeutical use of glutathione derivatives
05/31/1995EP0655455A1 Novel phosporus containing pyridine derivatives
05/31/1995EP0655442A1 Piperazine derivatives as Tachykinin antagonists
05/31/1995EP0655440A2 1-Aminoethylindoles
05/31/1995EP0655251A1 Pharmaceutical composition for preventing or treating
05/31/1995EP0655245A2 Compositions and their use for retarding the aging process
05/31/1995EP0655063A1 Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension
05/31/1995EP0655056A1 Piperidinyl-terminated n-(dihydroxy alkyl)-ethynyl-alanine amides for treatment of hypertension
05/31/1995EP0655055A1 Tachykinin antagonists
05/31/1995EP0654999A1 Use of inhibitors of vacuolar-type h?+ atpases
05/31/1995EP0654994A1 Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
05/31/1995EP0654993A1 Method for destroying or inhibiting growth of unwanted cells or tissues
05/31/1995EP0576420B1 Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it
05/31/1995EP0542912B1 Calcium and trace mineral supplements
05/31/1995EP0515462B1 Indole derivatives, their preparation and use
05/31/1995CN1028655C NF-1616-904 oxide of pyrazine and medicine composition contained this compound
05/30/1995US5420339 Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
05/30/1995US5420298 Pyrrolidine derivatives
05/30/1995US5420297 Peptides having substance P antagonistic activity
05/30/1995US5420296 Angiogenesis inhibitors and cardiovascular disorders
05/30/1995US5420292 Biphenyl-tetrazole intermediate compounds
05/30/1995US5420287 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
05/30/1995US5420273 Condensed heterocyclic compounds
05/30/1995US5420243 Transforming growth factor
05/30/1995US5420158 Melatonin activity
05/30/1995US5420157 Anticancer agents
05/30/1995US5420143 Piperidine derivatives for treating allergy
05/30/1995US5420138 Bicyclic pyridines which are angiotensin II inhibitors
05/30/1995US5420135 Substituted quinoline derivatives
05/30/1995US5420134 Substituted hexahydrobenzo[A]phenanthridines
05/30/1995US5420132 Substituted benzodioxins
05/30/1995US5420131 Platelet activating factor antagonist or 5-lipoxygenase inhibitors
05/30/1995US5420129 Treatment of hypertension, ischemia, vasospasms, angina
05/30/1995US5420127 Morpholino-terminated non-peptidyl α-succinamidoacyl aminodiols as anti-hypertensive agents
05/30/1995US5420109 Cytokine restraining agents
05/30/1995CA2136712A1 Piperazine derivatives
05/30/1995CA2066525C Synergistic combinations in the treatment of anxiety
05/30/1995CA2050303C Drugs (calcitonin gene-related peptides) for treating erectile dysfunctions
05/30/1995CA2048235C Lowering of blood uric acid levels
05/30/1995CA1335733C 1h-indazole-3-acetic acids as aldose reductase inhibitors
05/26/1995WO1995014025A1 Piperidinylcamphorsulfonyl oxytocin antagonists
05/26/1995WO1995014017A1 Non-peptide tachykinin receptor antagonists
05/26/1995WO1995014007A1 Phenyl-alkyl imidazoles as h3-receptor antagonists
05/26/1995WO1995014004A1 Indole-derived azylpiperazines as ligands for 5ht1-like receptors 5ht1b and 5ht1d
05/26/1995WO1995013834A1 Chimeric oligonucleoside compounds
05/26/1995WO1995013827A1 A method for preventing or controlling cataract
05/26/1995WO1995013820A1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier
05/26/1995WO1995013816A1 Transdermal prostaglandin composition
05/26/1995WO1995013805A1 Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
05/26/1995WO1995013802A1 Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
05/26/1995WO1995013797A1 Interdigitation-fusion liposomes containing arachidonic acid metabolites
05/26/1995WO1995013767A1 Osteogenic product and process
05/26/1995CA2176747A1 Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
05/26/1995CA2176735A1 Non-peptide tachykinin receptor antagonists
05/26/1995CA2176721A1 Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
05/26/1995CA2176259A1 Chimeric oligonucleoside compounds
05/26/1995CA2175350A1 Interdigitation-fusion liposomes containing arachidonic acid metabolites
05/26/1995CA2174650A1 Piperidinyl camphorsulfonyl oxytocin antagonists
05/24/1995EP0654479A2 Esculetin derivatives and method for manufacture thereof, use thereof, and pharmaceutical composition
05/24/1995EP0654272A1 Alimentary canal cell activator
05/24/1995EP0654268A1 A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
05/24/1995EP0654265A1 Aromatase-inhibiting composition containing azole derivative
05/24/1995EP0654264A1 Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
05/24/1995EP0654024A1 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
05/24/1995EP0653943A1 Targeting somatic gene therapy to joints
05/24/1995EP0653942A1 Morphogen-induced nerve regeneration and repair
05/24/1995EP0653941A1 Targeted delivery of growth factors for bone regeneration
05/24/1995EP0653940A1 Glial mitogenic factors, their preparation and use
05/24/1995EP0653937A1 Chemical compounds
05/24/1995CN1102785A Kidney-tonifying and life-prolonging wine
05/24/1995CN1028531C 2-oxa-1-oxo-8-azaspiro ¾4,5 decane derivatives, pharmaceutical compositions containing them and process for preparing same
05/24/1995CN1028529C Interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in treatment of thrombotic and vasospastic disease
05/24/1995CA2136288A1 Imidazopyridazines
05/23/1995US5418252 Method for inhibiting cartilage degradation
05/23/1995US5418251 Topical composition for accelerating wound healing
05/23/1995US5418249 Renin inhibitors
05/23/1995US5418243 Anticholesterol agents
05/23/1995US5418237 Indole derivatives
05/23/1995US5418227 For treatment of estrogen deficiency symptoms
05/23/1995US5418224 Antibiotic
05/23/1995US5418222 Multi-layered collagen film compositions for delivery of proteins and methods of using same
05/23/1995US5418219 Pharmaceutical composition for treatment of adult respiratory distress syndrome containing human ANP
05/23/1995US5418157 Recombinant 68,000 dalton collagenase of Clostridium histolyticum
05/19/1995CA2134149A1 Compounds containing a fused multiple ring lactam
05/19/1995CA2118443A1 Aromatase-inhibiting composition containing azole derivative
05/18/1995WO1995013365A1 Generation of high titers of recombinant aav vectors
05/18/1995WO1995013302A1 Cathepsin-l-specific inhibitor polypeptide
05/18/1995WO1995013289A1 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
1 ... 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 ... 1564